Skip To Main Content
Heidi Ledford on Muck Rack

Heidi Ledford

Verified
Seattle
As seen in: Nature, British Journal of Cancer, TIME, Scientific American, Flipboard, Salon, Yahoo, Genetic Literacy Project, Spektrum.de, Rebelion, RealClear Science and
Science reporter @nature mostly covering biomedicine. Views my own. She/her. PhD.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Heidi

Contact Heidi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Exclusive: the science papers that patents cite the most

|
By Richard Van Noorden Verified, Heidi Ledford Verified, Edward H. Chen
| Nature Verified
Half a century ago, biochemists Georges Köhler and César Milstein kicked off a revolution in medicine. Their 1975 paper described how to mass-produce monoclonal antibodies: proteins that can be designed to recognize and bind specifically to almost any protein target1. These antibodies have since become a workhorse of biological research and the basis of blockbuster treatments for cancer, autoimmune conditions and infectious diseases.
Open in Who Shared Issue with article?

Exclusive: the science papers that patents cite the most

|
By Richard Van Noorden Verified, Heidi Ledford Verified, Edward H. Chen
| Flipboard
Trucks 1 hour ago 5 Car Brands With Plans To Bring Back The Mid-Gate Pickup slashgear.com - Mike Garrett • 1h It's hard to understate the importance of the pickup truck in America as both an economic and cultural force.
Open in Who Shared Issue with article?

Cancer-fighting antibodies with a one-two punch take aim at tumours

|
By Heidi Ledford Verified
| Nature Verified
Bispecific antibodies (orange and yellow, artist’s illustration) grab onto two different proteins rather than the standard one.Credit: Thom Leach/Science Photo Library Cancer-fighting drugs called bispecific antibodies are having a moment. A growing number are making their way into the clinic, and researchers are developing increasingly elaborate molecules with new capabilities.
Open in Who Shared Issue with article?
See all 697 articles